DENSE-AIR
5.6.2019 17:19:03 CEST | Business Wire | Press release
Dense Air & Dublin City Council win the 2019 Small Cell Forum Award for Social Impact – ‘Promoting Small Cells for Social/Economic/Environmental Development’. It follows successful completion of the first phase of a ground breaking 5G research and development network in Dublin’s Docklands delivered as part of the Dublin City Council (DCC) ‘Smart Docklands’ initiative.
This strategic partnership between Dense Air and DCC announced in January 2018 was intended to provide a framework for the large-scale deployment of a “pervasive” 5G connectivity solution across Dublin, and also intended to develop a blue print for future deployments globally. The initial findings have demonstrated that Neutral Host Small Cells can provide unrivalled benefits to cities and mobile operators.
Working with City council departments, national agencies, building owners and the Science Foundation Ireland CONNECT Research Centre for future networks based in TCD, Dense Air have focused on understanding how best to deploy small cells on city owned street assets build neutral-host infrastructure that can be used simultaneously, by multiple mobile network providers and private networks to simplify the small cell installation process. Having an efficient, affordable, scalable and repeatable processes, are key factors in deploying 5G small cells networks, where densification and improved indoor performance will require access to city street assets including lamp posts and traffic lights.
The judging panel stated that: “There are many interesting smart city projects involving small cells but the collaboration between Dense Air and Dublin City Council stands out for the variety of services supported, and well-quantified benefits to citizens, businesses and visitors The judges were also impressed by the neutral host model, which they believe will be very significant in lowering barriers to deployment of large networks.”
Jamie Cudden, Smart City Program Manager said:“Dublin City Council is delighted to be recognised by the Small Cell Forum for our collaboration with Dense Air. The delivery of this project was only possible through collaboration with the CONNECT research centre for future networks, local building owners and the engagement of our wider Smart Docklands partner network.
“Pervasive connectivity offers cities a clear competitive advantage and we are now ideally placed to provide a perfect live 5G test environment for companies to work with us to trial services that can help us solve different challenges. Furthermore Dublin is now providing other cities globally a template for how they can realise the future 5G opportunity.”
Paul Senior , CEO of Dense Air said “We are absolutely thrilled to have received two awards at the 2019 Small Cell Forum World Summit in London. These awards recognise Dense Air’s unique neutral host business model based on densification using small cells, and deployment and engagement we have with cities, namely Dublin City Council.”
Building on the success of this project, Dublin City Council will host the prestigious Harvard TECH Innovators Forum in partnership with Dense Air from 7-9th October 2019; Bringing together city technology leaders from across the world to share emerging best practice for 5G deployments and showcasing the Dublin Docklands 5G Pervasive Network.
Dr. David Ricketts, Innovation Fellow in the Technology in Entrepreneurship Center at Harvard (TECH) comments that, ”We are delighted to bring together cities in Dublin to share best practice experiences on how they can manage disruptive technologies in a way that will allow us to build better communities for everyone. This unique gathering will bring the top global city technology leaders together to better understand how cities can best leverage and lead on the 5G opportunity.”
https://theinnovatorsforum.org/
Dense Air is headquartered in London, UK and has offices in the target launch markets of Ireland, Belgium, Portugal, Australia & New Zealand. Dense Air provides a unique “carrier of carriers” wholesale neutral host small cell services to deliver cost-effective densification to existing mobile carriers or service providers. Dense Air is conducting extensive trials and proof-of-concepts in 2019 and will offer commercial services in 2020. Dense Air provides small cell services in Ireland based on licensed 3.4-3.8GHz radio spectrum awarded by Ireland regulator in 2017.
Dublin City Council (DCC) is leading a series of innovative partnerships with world-leading technology companies through its Smart Dublin initiative. The Smart Docklands district was set up in February 2018 to deliver and fast-track smart city projects and deployments and understand the different types of connectivity and networks that would enable future cities. This was established in partnership with CONNECT, a national research centre for connectivity and future networks. Smart Docklands was a first of its kind in Ireland, where the municipality and academia have created a dedicated Project Management Office (PMO) to play an independent role amongst multiple stakeholders, from global technology companies to local residents’ groups, from academic institutions to international property developers, innovative start-ups and SMEs to fast track emerging smart city opportunities. http://smartdocklands.ie/
View source version on businesswire.com: https://www.businesswire.com/news/home/20190605005708/en/
Contact:
Dense Air Paul Coffey Tel: 01895 467100 www.denseair.net
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
